Asia Pacific Branded Generics Market Size & Outlook
Asia Pacific branded generics market, 2018-2030 (US$M)
Related Markets
Asia Pacific branded generics market highlights
- The Asia Pacific branded generics market generated a revenue of USD 107.6 billion in 2021.
- The market is expected to grow at a CAGR of 6.4% from 2022 to 2030.
- In terms of segment, anti-hypertensive was the largest revenue generating drug class in 2021.
- Anti-hypertensive is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2022 to 2030.
Asia Pacific data book summary
| Market revenue in 2021 | USD 107.6 billion |
| Market revenue in 2030 | USD 188.0 billion |
| Growth rate | 6.4% (CAGR from 2021 to 2030) |
| Largest segment | Anti-hypertensive |
| Fastest growing segment | Anti-hypertensive |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD billion |
| Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
| Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 47.0% of the global branded generics market in 2021.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 188.0 billion by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Branded Generics Market Scope
Branded Generics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific branded generics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 15.71% in 2021. Horizon Databook has segmented the Asia Pacific branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific market is expected to witness lucrative growth over the forecast period due to the proactive government initiatives and collaborative efforts to improve access to generic medications & reduce the healthcare expenditure on pharmaceuticals. This region consists of a blend of developing and developed economies.
Owing to improper reimbursement scenarios and low disposable income in developing and lowincome countries, there is a high demand for low-cost drugs. Such factors could create opportunities for branded generics players.
Countries in this region are focusing on the development of their manufacturing hubs to tackle the shortage of life-saving medicines, addressing the unmet needs. Countries like India may witness fast growth due to the increase in export of generic medications.
Reasons to subscribe to Asia Pacific branded generics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific branded generics market databook
-
Our clientele includes a mix of branded generics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific branded generics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific branded generics market size, by country, 2018-2030 (US$M)
Asia Pacific Branded Generics Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
